Investigation of FOXM1 as a Potential New Target for Melanoma

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Miyashita, Azusa ^a   Fukushima, Satoshi ^a   Nakahara, Satoshi ^a   Yamashita, Junji ^a   Tokuzumi, Aki ^a   Aoi, Jun ^a   Ichihara, Asako ^a   Kanemaru, Hisashi ^a   Jinnin, Masatoshi ^a   Ihn, Hironobu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FORKHEAD TRANSCRIPTION FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FORKHEAD BOX M1; UNCLASSIFIED DRUG; FORKHEAD BOX PROTEIN M1; FOXM1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; MELANOMA CELL LINE; METASTATIC MELANOMA; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; INFANT; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; TUMOR CELL LINE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; FEMALE; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; MALE; MAP KINASE SIGNALING SYSTEM; MELANOMA; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84955603109     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144241     Document Type: Article

References (34)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300. doi: 10.3322/caac.20073 PMID: 20610543.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. doi: 10.1056/ NEJMoa1003466 PMID: 20525992; PubMed Central PMCID: PMCPMC3549297.
3. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled Analysis of Long- Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015; 33(17):1889-94. doi: 10.1200/JCO.2014.56.2736 PMID: 25667295.
4. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373(1):23-34. doi: 10.1056/ NEJMoa1504030 PMID: 26027431.
5. Wang X, Kiyokawa H, Dennewitz MB, Costa RH. The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc Natl Acad Sci U S A. 2002; 99(26):16881-6. doi: 10.1073/pnas.252570299 PMID: 12482952; PubMed Central PMCID: PMCPMC139238.
6. Wonsey DR, Follettie MT. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 2005; 65(12):5181-9. doi: 10.1158/0008-5472.CAN-04- 4059 PMID: 15958562.
7. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007; 7(11):847-59. doi: 10.1038/nrc2223 PMID: 17943136.
8. Raychaudhuri P, Park HJ. FoxM1: a master regulator of tumor metastasis. Cancer Res. 2011; 71 (13):4329-33. doi: 10.1158/0008-5472.CAN-11-0640 PMID: 21712406; PubMed Central PMCID: PMCPMC3129416.
9. Yokomine K, Senju S, Nakatsura T, Irie A, Hayashida Y, Ikuta Y, et al. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy. Int J Cancer. 2010; 126(9):2153-63. doi: 10.1002/ijc.24836 PMID: 19688828.
10. Wang M, Gartel AL. The suppression of FOXM1 and its targets in breast cancer xenograft tumors by siRNA. Oncotarget. 2011; 2(12):1218-26. PMID: 22203467; PubMed Central PMCID: PMCPMC3282079.
11. Bhat UG, Halasi M, Gartel AL. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS One. 2009; 4(5):e5592. doi: 10.1371/journal.pone.0005592 PMID: 19440351; PubMed Central PMCID: PMCPMC2680058.
12. Teh MT, Gemenetzidis E, Patel D, Tariq R, Nadir A, Bahta AW, et al. FOXM1 induces a global methylation signature that mimics the cancer epigenome in head and neck squamous cell carcinoma. PLoS One. 2012; 7(3):e34329. doi: 10.1371/journal.pone.0034329 PMID: 22461910; PubMed Central PMCID: PMCPMC3312909.
13. Wang Z, Banerjee S, Kong D, Li Y, Sarkar FH. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007; 67 (17):8293-300. doi: 10.1158/0008-5472.CAN-07-1265 PMID: 17804744.
14. Teh MT, Wong ST, Neill GW, Ghali LR, Philpott MP, Quinn AG. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res. 2002; 62(16):4773-80. PMID: 12183437.
15. Wang Z, Li Y, Ahmad A, Banerjee S, Azmi AS, Kong D, et al. Down-regulation of Notch-1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. J Cell Biochem. 2011; 112(1):78-88. doi: 10.1002/jcb.22770 PMID: 20658545.
16. Bhat UG, Zipfel PA, Tyler DS, Gartel AL. Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle. 2008; 7(12):1851-5. PMID: 18583930.
17. Huynh KM, Soh JW, Dash R, Sarkar D, Fisher PB, Kang D. FOXM1 expression mediates growth suppression during terminal differentiation of HO-1 human metastatic melanoma cells. J Cell Physiol. 2011; 226(1):194-204. doi: 10.1002/jcp.22326 PMID: 20658516.
18. Bonet C, Giuliano S, Ohanna M, Bille K, Allegra M, Lacour JP, et al. Aurora B is regulated by the mitogen- activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells. J Biol Chem. 2012; 287(35):29887-98. doi: 10.1074/ jbc.M112.371682 PMID: 22767597; PubMed Central PMCID: PMCPMC3436153.
19. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011; 10(3):385-94. doi: 10.1158/1535-7163.MCT-10-0799 PMID: 21388974.
20. Slipicevic A, Holm R, Nguyen MT, Bøhler PJ, Davidson B, Flørenes VA. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol. 2005; 124 (4):528-36. doi: 10.1309/YT58WWMTA6YR1PRV PMID: 16146807.
21. Major ML, Lepe R, Costa RH. Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol Cell Biol. 2004; 24(7):2649-61. PMID: 15024056; PubMed Central PMCID: PMCPMC371108.
22. Park HJ, Carr JR, Wang Z, Nogueira V, Hay N, Tyner AL, et al. FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J. 2009; 28(19):2908-18. doi: 10.1038/emboj.2009.239 PMID: 19696738; PubMed Central PMCID: PMCPMC2760115.
23. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009; 27(36):6199-206. doi: 10.1200/JCO. 2009.23.4799 PMID: 19917835; PubMed Central PMCID: PMCPMC2793035.
24. Ma RY, Tong TH, Cheung AM, Tsang AC, Leung WY, Yao KM. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J Cell Sci. 2005; 118(Pt 4):795-806. doi: 10.1242/jcs.01657 PMID: 15671063.
25. Ye H, Kelly TF, Samadani U, Lim L, Rubio S, Overdier DG, et al. Hepatocyte nuclear factor 3/fork head homolog 11 is expressed in proliferating epithelial and mesenchymal cells of embryonic and adult tissues. Mol Cell Biol. 1997; 17(3):1626-41. PMID: 9032290; PubMed Central PMCID: PMCPMC231888.
26. Feng Y, Wang L, Zeng J, Shen L, Liang X, Yu H, et al. FoxM1 is overexpressed in Helicobacter pyloriinduced gastric carcinogenesis and is negatively regulated by miR-370. Mol Cancer Res. 2013; 11 (8):834-44. doi: 10.1158/1541-7786.MCR-13-0007 PMID: 23576572.
27. Chen B, Tardell C, Higgins B, Packman K, Boylan JF, Niu H. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One. 2012; 7(8):e42598. doi: 10.1371/journal.pone. 0042598 PMID: 22880048; PubMed Central PMCID: PMCPMC3411810.
28. McArthur GA. Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma:We are not Done Yet. Front Oncol. 2015; 5:161. doi: 10.3389/fonc.2015.00161 PMID: 26236691; PubMed Central PMCID: PMCPMC4505146.
29. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol. 1999; 154 (3):745-54. doi: 10.1016/S0002-9440(10)65321-7 PMID: 10079252; PubMed Central PMCID: PMCPMC1866429.
30. Janitz M, Fiszer D, Michalczak-Janitz K, Lukaszyk A, Fernandez N, SkorupskiW, et al. Analysis of mRNA for class I HLA on human gametogenic cells. Mol Reprod Dev. 1994; 38(2):231-7. doi: 10.1002/ mrd.1080380215 PMID: 8080653.
31. Fukushima S, Hirata S, Motomura Y, Fukuma D, Matsunaga Y, Ikuta Y, et al. Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells. J Immunother. 2009; 32(3):219-31. doi: 10.1097/CJI. 0b013e318194b63b PMID: 19242378.
32. Bektas N, Haaf A, Veeck J, Wild PJ, Lüscher-Firzlaff J, Hartmann A, et al. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer. 2008; 8:42. doi: 10.1186/1471-2407-8-42 PMID: 18254960; PubMed Central PMCID: PMCPMC2265720.
33. Priller M, Pöschl J, Abrão L, von Bueren AO, Cho YJ, Rutkowski S, et al. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. Clin Cancer Res. 2011; 17(21):6791-801. doi: 10.1158/1078-0432.CCR-11-1214 PMID: 21918172.
34. Yamashita J, Fukushima S, Jinnin M, Honda N, Makino K, Sakai K, et al. Kinesin family member 20A is a novel melanoma-associated antigen. Acta Derm Venereol. 2012; 92(6):593-7. doi: 10.2340/ 00015555-1416 PMID: 22854760.